Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Morning. Today we look at the FDA cracking down on compounding pharmacies over GLP-1s, we discuss the U.K. pharma breakdown further, and more.

FDA cracks down on GLP-1 compounding claims

The FDA earlier this week issued nearly 60 warning letters to telehealth firms, med spas, and providers marketing compounded versions of blockbuster GLP-1 weight loss drugs, accusing them of misleadingly suggesting their products are equivalent to FDA-approved medications like Wegovy and Zepbound.

To read the rest of this story subscribe to STAT+. Subscribe Log In

See Full Page